Matthew Scholz

Matthew is the founder and CEO of Oisin Biotechnologies, a novel senolytic drug discovery company and its first spinout in cancer treatment, OncoSenx. Prior to Oisin and OncoSenx, Matthew was the founder and CEO of Immusoft, a platform company treating a variety of genetic diseases using a new Immune System Programming concept, enabling efficient insertion of genes encoding therapeutic proteins into patient’s immune B cells.

Programming descriptions are generated by participants and do not necessarily reflect the opinions of SXSW.